Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. I Mab Biopharma
Thumbnail
April 21, 2022

Jumping aboard the Claudin18.2 bandwagon

Thumbnail
April 04, 2022

Swift resolution emerges to China's non-compliance

Article image
Vantage logo
March 11, 2022

Another strike for biotech: China

Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.

Article image
Vantage logo
January 26, 2022

Pfizer hopes Gilead’s CD47 issues aren’t catching

Article image
Vantage logo
November 10, 2021

SITC 2021 – ALX Oncology's unpleasant double dip

Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.

Article image
Vantage logo
September 28, 2021

Biotech’s key fourth-quarter data 

Deciphera, Allakos and Uniqure are all set for important data disclosures.

Article image
Vantage logo
September 20, 2021

Esmo 2021 – Astra coasts towards a new lung cancer combo

Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.

Article image
Vantage logo
August 23, 2021

Trillium gets a buyout while it's down

The latest deal over a CD47 asset has got investors wondering who could be next.

Article image
Vantage logo
June 09, 2021

Asco 2021 movers – PDS wins, but big pharma reigns

PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.

Article image
Vantage logo
May 21, 2021

Asco 2021 – Abstract lift drives first stock moves

A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.

Article image
Vantage logo
March 29, 2021

Humanigen claims a Covid-19 win with lenzilumab

But the company focused on a modified intent-to-treat analysis of its pivotal trial.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.